Cytori Therapeutics, Inc.

First three patients treated in clinical safety and feasibility study for breast reconstruction

Published in MD Week, June 30th, 2006

Cytori Therapeutics, Inc. (CYTX)(XMPA) announced the enrollment and treatment of the first three patients in a study using adult adipose (fat)-derived stem and regenerative cells for breast reconstruction cancer therapy.

This investigator-initiated study is being conducted by Keizo Sugimachi, MD, president, Kyushu Central Hospital in Fukuoka Japan, using Cytori's regenerative cell processing system.

"We believe adipose stem and regenerative cells can have an important impact on the overall treatment of breast cancer patients," said Sugimachi. "If we can successfully use these cells, which are relatively easy to obtain, in conjunction with the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of MD Week

Source: MD Week (2006-06-30)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry